Protocol for PD SENSORS: Parkinson’s Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measuRes using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinson’s disease
Catherine Morgan,
Walter Maetzler,
Oliver Watson,
Lynn Rochester,
Ian Craddock,
Helen Matthews,
Emma L Tonkin,
Kirsi M Kinnunen,
Roisin McNaney,
Sam Whitehouse,
Majid Mirmehdi,
Farnoosh Heidarivincheh,
Ryan McConville,
Julia Carey,
Michal Rolinski,
Rachel Eardley,
Alan L Whone
Affiliations
Catherine Morgan
3 Cerebral Palsy Alliance, The University of Sydney, Sydney, New South Wales, Australia
Walter Maetzler
Department of Neurology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany
Oliver Watson
Infectious Disease Epidemiology, Imperial College London, London, UK
Lynn Rochester
Translational and Clinical Research Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, Newcastle upon Tyne, UK
Ian Craddock
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Helen Matthews
13 Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
Emma L Tonkin
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Kirsi M Kinnunen
Research and Development, IXICO, London, UK
Roisin McNaney
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Sam Whitehouse
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Majid Mirmehdi
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Farnoosh Heidarivincheh
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Ryan McConville
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Julia Carey
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Michal Rolinski
Translational Health Sciences, University of Bristol Medical School, Bristol, UK
Rachel Eardley
School of Computer Science, Electrical and Electronic Engineering and Engineering Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK
Alan L Whone
Translational Health Sciences, University of Bristol Medical School, Bristol, UK
Introduction The impact of disease-modifying agents on disease progression in Parkinson’s disease is largely assessed in clinical trials using clinical rating scales. These scales have drawbacks in terms of their ability to capture the fluctuating nature of symptoms while living in a naturalistic environment. The SPHERE (Sensor Platform for HEalthcare in a Residential Environment) project has designed a multi-sensor platform with multimodal devices designed to allow continuous, relatively inexpensive, unobtrusive sensing of motor, non-motor and activities of daily living metrics in a home or a home-like environment. The aim of this study is to evaluate how the SPHERE technology can measure aspects of Parkinson’s disease.Methods and analysis This is a small-scale feasibility and acceptability study during which 12 pairs of participants (comprising a person with Parkinson’s and a healthy control participant) will stay and live freely for 5 days in a home-like environment embedded with SPHERE technology including environmental, appliance monitoring, wrist-worn accelerometry and camera sensors. These data will be collected alongside clinical rating scales, participant diary entries and expert clinician annotations of colour video images. Machine learning will be used to look for a signal to discriminate between Parkinson’s disease and control, and between Parkinson’s disease symptoms ‘on’ and ‘off’ medications. Additional outcome measures including bradykinesia, activity level, sleep parameters and some activities of daily living will be explored. Acceptability of the technology will be evaluated qualitatively using semi-structured interviews.Ethics and dissemination Ethical approval has been given to commence this study; the results will be disseminated as widely as appropriate.
